文献速递妇科产科

异硫蓝与吲哚菁绿机器人前哨淋巴结评估用于子宫内膜癌的前瞻性临床试验及超分期影响(NCT01818739)

Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739).
PubMed 文献 · Gynecol Oncol · 2019-04-04

该前瞻性临床试验纳入204例子宫内膜癌患者,宫颈注射异硫蓝(ISB)和吲哚菁绿(ICG)后行前哨淋巴结(SLN)活检及盆腔淋巴结清扫。184例(90.2%)成功检出至少一枚SLN,ICG在半盆腔检出率83%高于ISB的64%(p<0.0001)。SLN算法检出阳性淋巴结21/23(91.3%),阴性预测值98.9%;超分期额外发现11例孤立肿瘤细胞或微转移,使总阳性率升至17%、阴性预测值99%、灵敏度94%。

要点

  • ICG在半盆腔SLN检出率83%高于ISB的64%(p<0.0001)。
  • SLN算法检出阳性淋巴结21/23(91.3%),阴性预测值98.9%。
  • 超分期额外检出11例孤立肿瘤细胞或微转移,阴性预测值升至99%。

核心结论

  • 子宫内膜癌SLN评估可行且安全,阴性预测值高(99%)。
  • ICG检测SLN较ISB更有效。
  • 超分期可检出额外阳性淋巴结,但基于标准切片治疗似乎合理,需进一步研究。

研究设计与样本

  • 前瞻性临床试验,纳入204例子宫内膜癌患者,宫颈3点和9点浅层各注射1 mL ISB和1 mL ICG(1:25稀释)。
  • SLN活检后行完整盆腔淋巴结清扫(主动脉淋巴结清扫由术者决定)。
  • 淋巴结行标准H&E切片分析;SLN超分期回顾性进行,对治疗医生设盲。

主要发现

  • 204例患者接受染料注射,184例(90.2%)检出至少一枚SLN,138例(68%)双侧映射。
  • 在半盆腔成功映射的患者中,ICG检出SLN的比例为83%,ISB为64%(p<0.0001)。
  • 映射成功患者的中位BMI为35.7 kg/m2,未映射患者为40.1 kg/m2(p=0.01)。
  • 23例(11.3%)患者淋巴结阳性;应用SLN算法检出阳性淋巴结21/23(91.3%),阴性预测值98.9%(95%CI:96.01%至99.71%)。
  • 11例患者超分期检出SLN孤立肿瘤细胞(ITCs)或微转移,纳入后34例(17%)淋巴结阳性,阴性预测值升至99%,灵敏度94%;仅ITCs患者无复发。

关键数值与推荐

  • SLN算法检出阳性淋巴结21/23(91.3%),阴性预测值98.9%(95%CI:96.01%至99.71%)。
  • 纳入超分期检出的11例ITCs或微转移后,34例(17%)淋巴结阳性,阴性预测值99%,灵敏度94%。

临床怎么用

  • 子宫内膜癌SLN评估可行且安全,阴性预测值高(99%)。
  • ICG检测SLN较ISB更有效。
  • 作者认为基于标准切片治疗似乎合理,但需进一步研究。

局限性

  • 超分期为回顾性进行。
  • 作者结论指出需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the performance sentinel lymph node (SLN) biopsy and effect of ultrastaging in clinically early stage endometrial cancer. METHODS: Patients with endometrial cancer prospectively enrolled after informed consent was obtained. The cervix was injected superficially with 1 mL of ISB and 1 mL of ICG (diluted 1:25) at 3 and 9 o'clock each. SLN biopsy was followed by complete pelvic lymphadenectomy (aortic lymphadenectomy at the discretion of the surgeon). Lymph nodes (LNs) were analyzed by standard sectioning with H&E; ultrastaging of SLN was done retrospectively and blinded to treating physicians. RESULTS: 204 patients received dye injections. In 184 (90.2%) patients at least one SLN was identified. Of all patients, 138 (68%) had bilateral mapping. In the patients with successful mapping of a hemipelvis, ICG detected SLNs in 83% and ISB in 64% of cases (p < 0.0001). Median BMI (kg/m2) for patients with successful mapping was 35.7 compared to 40.1 for those who did not map (p = 0.01). Twenty-three (11.3%) patients had positive LNs. Applying the SLN algorithm, positive nodes were detected in 21/23 (91.3%). The negative predictive value (NPV) was 98.9% (95% CI: 96.01% to 99.71%). Eleven patients had positive SLN with isolated tumor cells (ITCs) or micrometastases detected on ultrastaging. Including these patients, 34 (17%) had positive LNs, increasing the NPV to 99% and sensitivity to 94%. There were no recurrences in patients with ITCs only. CONCLUSIONS: SLN assessment in endometrial cancer is feasible and safe with high NPV (99%). ICG was more effective in detecting SLN compared to ISB. Although ultrastaging detected additional positive LNs, treatment based on standard sectioning appears reasonable but further research is needed.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Backes FJ, Cohen D, Salani R, et al. Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). Gynecol Oncol. 2019. PMID: 31230614. doi:10.1016/j.ygyno.2019.03.252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。